Table 4.

Association Between the Incidence of Immune-Related Adverse Events and the Change in the Post-Treatment Relative Eosinophil Count

	Increased REC (n=65)	Decreased REC (n=40)	p value
Any-grade irAEs, n (%)	21 (32.3)	13 (32.5)	1.000
Skin	12 (18.5)	3 (7.5)	0.156
Endocrine	5 (7.7)	6 (15.0)	0.326
Gastrointestinal	3 (4.6)	4 (10.0)	0.423
Respiratory	3 (4.6)	1 (2.5)	1.000
Hepatobiallary	0	2 (5.0)	0.143
Grade 3 irAEs, n(%)	7 (10.8)	4 (10.0)	1.000

Abbreviations: irAEs, immune-related adverse events; REC, relative eosinophil count.